Due to NAPRT overexpression potentially causing resistance to DNA-damaging agents, the enzyme could act as a possible therapeutic target for patients with BRCA-mutated ovarian cancer to prevent or reverse treatment resistance. Here, NAPRT is linked to ovarian carcinoma.